Journal of Pharmaceutical Sciences 2013-07-01

Rimonabant dimorphism and its pressure-temperature phase diagram: a delicate case of overall monotropic behavior.

Marc-Antoine Perrin, Michel Bauer, Maria Barrio, Josep-Lluís Tamarit, René Céolin, Ivo B Rietveld

Index: J. Pharm. Sci. 102(7) , 2311-21, (2013)

Full Text: HTML

Abstract

Crystalline polymorphism occurs frequently in the solid state of active pharmaceutical ingredients, and this is problematic for the development of a suitable dose form. Rimonabant, an active pharmaceutical ingredient developed by Sanofi and discontinued because of side effects, exhibits dimorphism; both solid forms have nearly the same melting temperatures, melting enthalpies, and specific volumes. Although the problem may well be academic from an industrial point of view, the present case demonstrates the usefulness of constructing pressure-temperature phase diagrams by direct measurement as well as by topological approach. The system is overall monotropic and form II is the more stable solid form. Interestingly, the more stable form does not possess any hydrogen bonds, whereas the less stable one does.Copyright © 2013 Wiley Periodicals, Inc.


Related Compounds

Related Articles:

Obesity drug therapy.

2013-09-01

[Minerva Endocrinol. 38(3) , 245-54, (2013)]

Anandamide-CB1 receptor signaling contributes to postnatal ethanol-induced neonatal neurodegeneration, adult synaptic, and memory deficits.

2013-04-10

[J. Neurosci. 33(15) , 6350-66, (2013)]

Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.

2013-09-01

[Yonsei Med. J. 54(5) , 1127-36, (2013)]

Peripherally restricted CB1 receptor blockers.

2013-09-01

[Bioorg. Med. Chem. Lett. 23(17) , 4751-60, (2013)]

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.

2014-02-15

[Am. J. Physiol. Endocrinol. Metab. 306(4) , E457-68, (2014)]

More Articles...